Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Taxol

Executive Summary

Bristol-Myers Squibb will move straight to the appeals stage in paclitaxel patent litigation with Ivax and other generic co-defendants, rather than go to trial over the patent claims remaining after a March 2 Newark, N.J. federal court decision of partial summary judgement. The appeal will focus on the patent claims dismissed by the decision, which invalidated the non-ovarian cancer claims. The decision also cleared the way for Ivax to launch its generic paclitaxel for breast cancer once its application is approved by FDA following the expiration of the 30-month Waxman/Hatch stay of approval in June (1"The Pink Sheet" March 6, p. 25)

You may also be interested in...



Ivax Generic Taxol Launch Could Come In June After Summary Judgment

Ivax plans to launch a generic version of Bristol-Myers Squibb's Taxol (paclitaxel) without waiting for Bristol to appeal a Newark, N.J. federal court summary judgment that deems the majority of Bristol's paclitaxel patent claims invalid.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel